Comparison · NCT04752566-1700a875
Eculizumab vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Eculizumab vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs). Trial comparisons, record NCT04752566-1700a875. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04752566-1700a875
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.919 | 0.787 | 0.972 | wilson | |
| Risk in group 2 | 0.95 | 0.764 | 0.991 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0311 | -0.169 | 0.162 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.967 | 0.842 | 1.11 | log | |
| Odds ratio, group 1 over group 2 | 0.596 | 0.0579 | 6.14 | log | |
| Number needed to treat, for one fewer participant with the outcome on Eculizumab than on Placebo | 32.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Eculizumab | Participants received eculizumab IV infusion on Days 1, 8, 15, and 22. | 34 | 37 | OG000 |
| Group 2 | Placebo | Participants received placebo matched to eculizumab via IV infusion on Days 1, 8, 15, and 22. | 19 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Description
TEAEs were defined as an adverse event (AE) with onset on or after the first dose of the study drug. An AE is any untoward medical occurrence in a participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
- Time frame
- Day 1 up to Week 24
- Population
- Safety set included all participants who received at least 1 dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
- NCT number
- NCT04752566
- Phases
- PHASE3
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Eculizumab, Placebo
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Results first posted
- 2024-02-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04752566?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04752566-1700a875